German Drug Report Could Mean More Pressure On Pharma Revenues
This article was originally published in The Pink Sheet Daily
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.
You may also be interested in...
European Notebook: CHMP Opens Up A Bit; France Looks For $1B In Price Cuts; Spain Making Good On Pharma Debts
Europe's top scientific advisory panel, the CHMP, could reveal more of its thoughts on product approvals next year. French biopharma tries to stave off deep cuts in budgetary debate; Germany may consider more health reforms following recent elections; Invesco, Servier see exec changes
The positive financial prognosis for German health insurers might prompt the government to look at removing the drug price rise moratorium and obligatory rebate.
Counterfeit omeprazole has been found for the third time in Germany, suggesting that the generics sector must raise its game to combat this phenomenon.